Fig. 6 | Scientific Reports

Fig. 6

From: A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation

Fig. 6

Hesperetin recovers decreased process elongation under various experimental conditions. (A, B) Following the induction of differentiation, N1E-115 cells were treated with reserpine and hesperetin (Hes) or its vehicle and cultured for 3 days. The morphology of the cells at day 0 is also depicted in the diagram. Cells with processes were counted and graphically represented (** p < 0.01; n = 10 fields). (C, D) Following the induction of differentiation, cells were treated with tetrabenazine and hesperetin or its vehicle and cultured for 3 days. The morphology of the cells at day 0 is also depicted in the diagram. Cells with processes were counted and graphically represented (** p < 0.01; n = 10 fields). (E, F) Following the induction of differentiation, cells transfected with Cas13 and VMAT-2 gRNA (gVMAT-2) were treated with hesperetin or its vehicle and cultured for 3 days. The morphology of the cells at day 0 is also depicted in the diagram. Cells with processes were counted and graphically represented (** p < 0.01; n = 10 fields).

Back to article page